Source: Business Wire MALVERN, Pa.--(BUSINESS WIRE)--Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated…...
Latest News
Datavant Acquires Universal Patient Key and Closes $40M Financing Round
Source: PR Newswire SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Datavant, the leader in helping healthcare organizations safely link their…...
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
Source: "Sun Pharma" and includes its subsidiaries and/or associate companies) announced that the U.S. Food and Drug Administration (FDA) has…...
Cigna to Acquire Express Scripts for $67 Billion
Source: Drives greater affordability and connectivity with customers and their health care providers, while making health care simpler Creates an…...
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
Source: WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient…...
QFR Solutions Earns Another Top Spot
Source: LinkedIn QFR Solutions has earned another Top spot in LinkedIn’s Top 25 Most Socially Engaged Staffing Agencies. This is…...
Celgene’s $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?
Source: Forbes Last night, Celgene announced that it is buying Impact BioMedicines, a small biotech developing a drug to compete…...
Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
Source: Aclaris Therapeutics MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today…...
Dr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
Source: Business Wire December 01, 2017 01:05 AM Eastern Standard Time HYDERABAD, India & PRINCETON, N.J. & MALVERN, Pa.-- Dr.…...
AbbVie’s risankizumab blows away aging rivals in phase 3
Source: FierceBiotech AbbVie has posted positive phase 3 psoriasis data on potential blockbuster risankizumab. The IL-23 antibody easily outperformed Johnson…...